OMERS ADMINISTRATION Corp Purchases 28,000 Shares of Bruker Corporation $BRKR

OMERS ADMINISTRATION Corp boosted its position in shares of Bruker Corporation (NASDAQ:BRKR) by 15.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 212,200 shares of the medical research company’s stock after purchasing an additional 28,000 shares during the quarter. OMERS ADMINISTRATION Corp owned 0.14% of Bruker worth $8,743,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Parallel Advisors LLC boosted its position in shares of Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after purchasing an additional 347 shares in the last quarter. UMB Bank n.a. raised its stake in Bruker by 26.3% during the 2nd quarter. UMB Bank n.a. now owns 1,673 shares of the medical research company’s stock worth $69,000 after buying an additional 348 shares during the period. Hantz Financial Services Inc. lifted its holdings in Bruker by 39.5% during the second quarter. Hantz Financial Services Inc. now owns 1,560 shares of the medical research company’s stock worth $64,000 after acquiring an additional 442 shares in the last quarter. US Bancorp DE grew its stake in Bruker by 4.1% in the first quarter. US Bancorp DE now owns 12,313 shares of the medical research company’s stock valued at $514,000 after acquiring an additional 480 shares during the period. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Bruker by 377.5% in the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after acquiring an additional 487 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on BRKR. Wells Fargo & Company dropped their price target on Bruker from $50.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Redburn Partners set a $60.00 price target on shares of Bruker in a research note on Thursday, November 20th. Barclays upped their price target on shares of Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Rothschild & Co Redburn began coverage on shares of Bruker in a research report on Thursday, November 20th. They set a “buy” rating and a $60.00 price objective for the company. Finally, Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a “buy” rating in a report on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and an average price target of $50.25.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the sale, the director owned 18,016 shares in the company, valued at $581,016. This represents a 16.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director John A. Ornell sold 6,233 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director directly owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. The trade was a 15.04% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 27.30% of the company’s stock.

Bruker Stock Performance

Shares of BRKR stock opened at $47.75 on Monday. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $64.64. The company’s fifty day simple moving average is $38.89 and its 200-day simple moving average is $37.62. The firm has a market cap of $7.26 billion, a PE ratio of 91.83, a P/E/G ratio of 5.31 and a beta of 1.26. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. During the same period in the previous year, the business earned $0.60 EPS. The company’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities research analysts expect that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio is presently -125.00%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.